Neurocrine Biosciences (NBIX) News Today $142.74 +1.41 (+1.00%) Closing price 04:00 PM EasternExtended Trading$141.37 -1.37 (-0.96%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Neurocrine Biosciences Up Today?Toggle Visibility of Why Is Neurocrine Biosciences Up Today?Neurocrine Biosciences (NASDAQ: NBIX) is trading higher after a wave of analyst activity ahead of its Q3 2025 earnings release. Investors are responding to new coverage and price-target increases that signal upside, while some previews warn the company may not have the setup for an earnings beat. Watch the Oct. 28 post-close earnings report as a potential catalyst. Positive Sentiment: Citigroup initiated coverage with a Buy rating and a $175 price target, signaling roughly ~22.6% upside from current levels and likely helping lift sentiment around NBIX. Citigroup Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation Positive Sentiment: Morgan Stanley reiterated an Overweight rating and raised its price target to $168, supporting upside expectations and reinforcing buy-side conviction. Price Target Raised to $168.00 at Morgan Stanley Positive Sentiment: Analyst coverage summaries (12 reviews) and commentary highlight continued prescription growth and strategic positioning, adding to the constructive analyst narrative. Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews Neutral Sentiment: NBIX is scheduled to report Q3 2025 earnings after the close on Oct. 28 — this upcoming print is the main near-term catalyst and could swing the stock either way. NBIX Expected to Announce Quarterly Earnings on Tuesday Negative Sentiment: Zacks previews the earnings and warns NBIX may lack the right combination of factors for a likely beat despite expected year-over-year earnings growth — a cautionary note that could cap near-term gains if the report disappoints. Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Posted 58m agoAI Generated. May Contain Errors. NBIX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Citigroup Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation2 hours ago | msn.comDemystifying Neurocrine Biosciences: Insights From 12 Analyst ReviewsOctober 21 at 11:05 AM | benzinga.comMorgan Stanley Maintains Neurocrine Biosciences (NBIX) Overweight RecommendationOctober 21 at 11:05 AM | msn.comNeurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from Analysts at CitigroupOctober 21 at 8:09 AM | marketbeat.comNeurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on TuesdayOctober 21 at 4:42 AM | marketbeat.com85,123 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by VIRGINIA RETIREMENT SYSTEMS ET AlOctober 21 at 4:41 AM | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $168.00 at Morgan StanleyOctober 20 at 1:36 PM | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by New York State Teachers Retirement SystemOctober 19 at 4:30 AM | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Bought by Stanley Laman Group Ltd.October 18 at 6:08 AM | marketbeat.comApplied Finance Capital Management LLC Invests $316,000 in Neurocrine Biosciences, Inc. $NBIXOctober 18 at 5:15 AM | marketbeat.comNeurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst ApproachesOctober 18 at 4:50 AM | seekingalpha.comCwm LLC Raises Holdings in Neurocrine Biosciences, Inc. $NBIXOctober 18 at 3:48 AM | marketbeat.comVanguard Personalized Indexing Management LLC Acquires 2,577 Shares of Neurocrine Biosciences, Inc. $NBIXOctober 18 at 3:47 AM | marketbeat.comNeurocrine presents new data from Phase 3, open-label KINECT 4 studyOctober 17, 2025 | msn.comNeurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg CapsulesOctober 17, 2025 | prnewswire.comNeurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Strong-Buy at Zacks ResearchOctober 17, 2025 | marketbeat.comCallan Family Office LLC Purchases New Position in Neurocrine Biosciences, Inc. $NBIXOctober 17, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 17, 2025 | marketbeat.comAware Super Pty Ltd as trustee of Aware Super Has $4.75 Million Position in Neurocrine Biosciences, Inc. $NBIXOctober 16, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Bought by Generali Asset Management SPA SGROctober 16, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Has $57.33 Million Position in Neurocrine Biosciences, Inc. $NBIXOctober 15, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by Aberdeen Group plcOctober 15, 2025 | marketbeat.comVontobel Holding Ltd. Has $517,000 Holdings in Neurocrine Biosciences, Inc. $NBIXOctober 14, 2025 | marketbeat.comUBS Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) StockOctober 10, 2025 | marketbeat.comUBS Maintains Neurocrine Biosciences (NBIX) Buy RecommendationOctober 10, 2025 | msn.comNeurocrine Biosciences' (NBIX) "Hold (C+)" Rating Reaffirmed at Weiss RatingsOctober 10, 2025 | marketbeat.comTruist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIXOctober 8, 2025 | marketbeat.comNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial ResultsOctober 7, 2025 | prnewswire.comNeurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry FranchiseOctober 7, 2025 | finance.yahoo.comA Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study ResultsOctober 7, 2025 | finance.yahoo.comNeurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc.October 7, 2025 | marketbeat.comNeurocrine presents new data from KINECT-HD2 study of ingrezzaOctober 6, 2025 | msn.comNeurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington ...October 6, 2025 | finance.yahoo.comNeurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease ChoreaOctober 6, 2025 | prnewswire.comPure Financial Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIXOctober 4, 2025 | marketbeat.comWashington Capital Management Inc. Purchases 1,800 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 29, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Raises Stock Position in Neurocrine Biosciences, Inc. $NBIXSeptember 28, 2025 | marketbeat.comShould You be Optimistic on Neurocrine Biosciences (NBIX)?September 25, 2025 | insidermonkey.comShould You be Optimistic on Neurocrine Biosciences (NBIX)?September 25, 2025 | finance.yahoo.comNeurocrine Biosciences, Inc. $NBIX Shares Sold by Assenagon Asset Management S.A.September 24, 2025 | marketbeat.comNeurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease BurdenSeptember 23, 2025 | prnewswire.comPromising Phase 2 Results and Safety Profile of Osavampator Justify Buy Rating for Neurocrine BiosciencesSeptember 23, 2025 | tipranks.comAvanza Fonder AB Sells 9,207 Shares of Neurocrine Biosciences, Inc. $NBIXSeptember 23, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given "Outperform" Rating at WedbushSeptember 22, 2025 | marketbeat.comWhere Neurocrine Biosciences Stands With AnalystsSeptember 22, 2025 | benzinga.comNeurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive DisorderSeptember 22, 2025 | prnewswire.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $170.00 at Needham & Company LLCSeptember 22, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 22, 2025 | marketbeat.comNeurocrine Biosciences, Inc. $NBIX Shares Purchased by Atle Fund Management ABSeptember 21, 2025 | marketbeat.comFulton Bank N.A. Invests $333,000 in Neurocrine Biosciences, Inc. $NBIXSeptember 21, 2025 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.230.50▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼2417▲NBIX Articles Average Week Get the Latest News and Ratings for NBIX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Neurocrine Biosciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Biogen News Today United Therapeutics News Today Incyte News Today Ionis Pharmaceuticals News Today Exact Sciences News Today Exelixis News Today BioMarin Pharmaceutical News Today Madrigal Pharmaceuticals News Today Repligen News Today Halozyme Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBIX Stock Alerts